Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind, international Phase III trial in 653 patients, 75% of patients given Kaletra had <400 copies of HIV RNA per
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury